BRAF and neoplasm: About 20 years ago [113], the discovery of BRAF mutations in the majority of melanomas changed the therapeutic perspective for this neoplasia; these oncogenic mutations are constitutively activating a signaling pathway—the MAPK pathway—which is at the root of melanomagenesis, supporting cell growth, survival, and spreading of malignant melanocytes.